WO2009082720A3 - Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9h-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as a2ar agonists - Google Patents

Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9h-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as a2ar agonists Download PDF

Info

Publication number
WO2009082720A3
WO2009082720A3 PCT/US2008/087875 US2008087875W WO2009082720A3 WO 2009082720 A3 WO2009082720 A3 WO 2009082720A3 US 2008087875 W US2008087875 W US 2008087875W WO 2009082720 A3 WO2009082720 A3 WO 2009082720A3
Authority
WO
WIPO (PCT)
Prior art keywords
purin
ynyl
furan
tetrahydro
dihydroxy
Prior art date
Application number
PCT/US2008/087875
Other languages
French (fr)
Other versions
WO2009082720A2 (en
Inventor
Robert Thompson
Anthony Beauglehole
Frank Schmidtmann
Jayson Rieger
Original Assignee
Pgx Health, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP08864942A priority Critical patent/EP2234490A4/en
Priority to US12/809,381 priority patent/US8252767B2/en
Priority to JP2010539923A priority patent/JP2011507907A/en
Priority to CN2008801251885A priority patent/CN101938906A/en
Priority to AU2008340186A priority patent/AU2008340186B2/en
Priority to NZ586670A priority patent/NZ586670A/en
Priority to CA2710151A priority patent/CA2710151A1/en
Priority to MX2010006645A priority patent/MX2010006645A/en
Application filed by Pgx Health, Llc filed Critical Pgx Health, Llc
Priority to EA201001031A priority patent/EA019244B1/en
Priority to BRPI0821071-3A priority patent/BRPI0821071A2/en
Publication of WO2009082720A2 publication Critical patent/WO2009082720A2/en
Publication of WO2009082720A3 publication Critical patent/WO2009082720A3/en
Priority to IL206477A priority patent/IL206477A0/en
Priority to ZA2010/04535A priority patent/ZA201004535B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention provides substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters and pharmaceutical compositions containg the same that are selective agonists of A2A adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.
PCT/US2008/087875 2007-12-20 2008-12-20 Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9h-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as a2ar agonists WO2009082720A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CA2710151A CA2710151A1 (en) 2007-12-20 2008-12-20 Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9h-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as a2ar agonists
JP2010539923A JP2011507907A (en) 2007-12-20 2008-12-20 Substituted 4- {3- [6-amino-9- (3,4-dihydroxy-tetrahydro-furan-2-yl) -9H-purin-2-yl] -prop-2-ynyl} -piperidine as an A2AR agonist -1-carboxylic acid ester
CN2008801251885A CN101938906A (en) 2007-12-20 2008-12-20 Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydrofuran-2-yl)-9H-purin-2-yl]-propan-2-ynyl}-piperidine-1-carboxylic acid ester as A2AR agonist
AU2008340186A AU2008340186B2 (en) 2007-12-20 2008-12-20 Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl} -piperidine-1-carboxylic acid esters as A2AR agonists
NZ586670A NZ586670A (en) 2007-12-20 2008-12-20 Substituted 4-{ 3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9h-purin-2-yl]-prop-2-ynyl} -piperidine-1-carboxylic acid esters as a2ar agonists
EP08864942A EP2234490A4 (en) 2007-12-20 2008-12-20 Substituted 4-{3-ý6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9h-purin-2-yl¨-prop-2-ynyl}-piperidine-1-carboxylic acid esters as a2ar agonists
MX2010006645A MX2010006645A (en) 2007-12-20 2008-12-20 Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl) -9h-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as a2ar agonists.
US12/809,381 US8252767B2 (en) 2007-12-20 2008-12-20 Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
EA201001031A EA019244B1 (en) 2007-12-20 2008-12-20 Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9h-purin-2-yl]-prop-2-ynyl}piperidine-1-carboxylic acid esters and use thereof
BRPI0821071-3A BRPI0821071A2 (en) 2007-12-20 2008-12-20 Substituted 4- {3- [6-amino-9- (3,4-dihydroxy-tetrahydro-furan-2-yl) -9h-p-urin-2yl] -prop-2-yl} -piperidine-1-carboxylic acid esters as a2ar agonists
IL206477A IL206477A0 (en) 2007-12-20 2010-06-17 Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9h-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as a2ar agonists
ZA2010/04535A ZA201004535B (en) 2007-12-20 2010-06-25 Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9h-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as a2ar agonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1530307P 2007-12-20 2007-12-20
US61/015,303 2007-12-20

Publications (2)

Publication Number Publication Date
WO2009082720A2 WO2009082720A2 (en) 2009-07-02
WO2009082720A3 true WO2009082720A3 (en) 2009-08-27

Family

ID=40788895

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/087875 WO2009082720A2 (en) 2007-12-20 2008-12-20 Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9h-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as a2ar agonists

Country Status (16)

Country Link
US (2) US8293720B2 (en)
EP (1) EP2234490A4 (en)
JP (1) JP2011507907A (en)
KR (1) KR20100103631A (en)
CN (1) CN101938906A (en)
AU (1) AU2008340186B2 (en)
BR (1) BRPI0821071A2 (en)
CA (1) CA2710151A1 (en)
EA (1) EA019244B1 (en)
IL (1) IL206477A0 (en)
MX (1) MX2010006645A (en)
NZ (1) NZ586670A (en)
SG (1) SG186676A1 (en)
UA (1) UA100035C2 (en)
WO (1) WO2009082720A2 (en)
ZA (1) ZA201004535B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ545787A (en) * 2001-10-01 2007-12-21 Univ Virginia 2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof
WO2006028618A1 (en) * 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
JP5046930B2 (en) * 2004-08-02 2012-10-10 ユニバーシティ オブ バージニア パテント ファウンデーション 2-propynyladenosine analogs with modified 5'-ribose groups having A2A agonist activity
WO2007120972A2 (en) * 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
SG11201407336PA (en) 2012-05-25 2015-03-30 Janssen Sciences Ireland Uc Uracyl spirooxetane nucleosides
US9822141B2 (en) 2012-08-01 2017-11-21 Lewis And Clark Pharmaceuticals, Inc. N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as A2A agonists
EP2879683B1 (en) 2012-08-01 2020-01-22 Lewis and Clark Pharmaceuticals, Inc. N-alkyl-alkynyladenosine-5-uronamide compounds as agonists of a2a receptor
KR102532198B1 (en) 2012-12-21 2023-05-11 얀센 바이오파마, 인코퍼레이트. Substituted nucleosides, nucleotides and analogs thereof
AU2019324170A1 (en) 2018-08-23 2021-02-18 Seagen, Inc. Anti-TIGIT antibodies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070270373A1 (en) * 2006-05-18 2007-11-22 Rieger Jayson M Substituted aryl piperidinylalkynyladenosines as A2AR agonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
NZ545787A (en) * 2001-10-01 2007-12-21 Univ Virginia 2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof
DE60318192T2 (en) * 2002-04-10 2008-04-30 The University Of Virginia Patent Foundation USE OF A2A ADENOSINE RECEPTOR AGONISTS AND ANTI-PATHOGENIC AGENTS CONTAINING COMBINATIONS IN THE TREATMENT OF INFLAMMATORY DISEASES
WO2004037804A1 (en) * 2002-10-22 2004-05-06 Oscotec Inc. Furan derivatives for preventing and curing osteoporosis and pharmaceutical compositions containing the same
WO2006028618A1 (en) * 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
JP5046930B2 (en) 2004-08-02 2012-10-10 ユニバーシティ オブ バージニア パテント ファウンデーション 2-propynyladenosine analogs with modified 5'-ribose groups having A2A agonist activity
GB0505219D0 (en) * 2005-03-14 2005-04-20 Novartis Ag Organic compounds
WO2007120972A2 (en) * 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
GB0607951D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
US20080262001A1 (en) * 2007-04-23 2008-10-23 Adenosine Therapeutics, Llc Agonists of a2a adenosine receptors for treating recurrent tumor growth in the liver following resection
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070270373A1 (en) * 2006-05-18 2007-11-22 Rieger Jayson M Substituted aryl piperidinylalkynyladenosines as A2AR agonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MYERS ET AL.: "Potent Quinoxaline-Based Inhibitors of PDGf Receptor Tyrosine Kinase Activity.", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 13, no. 18, 15 September 2003 (2003-09-15), pages 3091 - 3095, XP008137767 *

Also Published As

Publication number Publication date
BRPI0821071A2 (en) 2015-06-16
US8252767B2 (en) 2012-08-28
ZA201004535B (en) 2012-09-26
EP2234490A4 (en) 2013-03-27
NZ586670A (en) 2012-10-26
UA100035C2 (en) 2012-11-12
AU2008340186A8 (en) 2010-07-29
MX2010006645A (en) 2010-10-05
US20090162292A1 (en) 2009-06-25
AU2008340186B2 (en) 2014-07-10
SG186676A1 (en) 2013-01-30
IL206477A0 (en) 2010-12-30
AU2008340186A1 (en) 2009-07-02
CN101938906A (en) 2011-01-05
KR20100103631A (en) 2010-09-27
WO2009082720A2 (en) 2009-07-02
CA2710151A1 (en) 2009-07-02
US8293720B2 (en) 2012-10-23
EA019244B1 (en) 2014-02-28
EP2234490A2 (en) 2010-10-06
US20110003765A1 (en) 2011-01-06
EA201001031A1 (en) 2011-02-28
JP2011507907A (en) 2011-03-10

Similar Documents

Publication Publication Date Title
WO2009082720A3 (en) Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9h-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as a2ar agonists
WO2006091898A3 (en) Pyrazolyl substituted xanthines
WO2005021548A3 (en) Substituted 8-heteroaryl xanthines
ZA200901036B (en) Adenosine derivatives as A2A receptor agonists
PL2018388T3 (en) Bisadenosine compounds as adenosine a2a receptor agonists
HK1209628A1 (en) Methods, compounds, compositions and vehicles for delivering 3-amino- 1-propanesulfonic acid 3--1-
DK2013211T3 (en) Purine derivatives for use as adenosine A2A receptor agonists
WO2008075101A3 (en) Improvements relating to laser marking
IL188725A0 (en) Pyrazine derivatives useful as adenosine receptor antagonists
HK1112458A1 (en) Purine derivatives acting as a2a receptor agonists
WO2007090071A3 (en) 6-modified bicyclic nucleic acid analogs
EP2012791A4 (en) 7,9-dihydro-purin-8-one and related analogs as hsp90-inhibitors
ZA200810671B (en) Purine derivatives as A2A agonists
MY152178A (en) Substituted 8-[6-amino-3-pyridyl]xanthines
WO2008011007A3 (en) Selective antagonists of a2a adenosine receptors
WO2006091936A3 (en) Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
WO2007109088A3 (en) Combinationtherapies of thiazolidinedione analogues and glucocorticoid agonists
WO2008116185A3 (en) Substituted pyrimidines as adenosine receptor antagonists
WO2008027585A3 (en) Pyrrolo[3,2-d]pyrimidines that are selective antagonists of a2b adenosine receptors
WO2007149277A3 (en) Substituted 8-[6-amino-3-pyridyl]xanthines
MX2012000113A (en) ALKOXY-CARBONYL-AMINO-ALKYNYL-ADENOSINE COMPOUNDS AND DERIVATIVES THEREOF AS A<sub>2A </sub>R AGONISTS.
ZA200806447B (en) Compounds useful as agonists of A2A adenosine receptors, cosmetic compositions with A2A agonists and a method for using the same
WO2008038094A3 (en) Process for the preparation of pure adenosine
ZA200900627B (en) Selective antagonists of A2A adenosine receptors
PL378983A1 (en) Xanthine derivatives as a2b adenosine receptor antagonists

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880125188.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08864942

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/006645

Country of ref document: MX

Ref document number: 12010501370

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2010539923

Country of ref document: JP

Ref document number: 2710151

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008340186

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 586670

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 4246/CHENP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008864942

Country of ref document: EP

Ref document number: 201001031

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 20107016275

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201009037

Country of ref document: UA

ENP Entry into the national phase

Ref document number: 2008340186

Country of ref document: AU

Date of ref document: 20081220

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PI 2010002822

Country of ref document: MY

WWE Wipo information: entry into national phase

Ref document number: 12809381

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0821071

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100617